Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA

2005 ◽  
Vol 23 (S1) ◽  
pp. 75-89 ◽  
Author(s):  
Natalie Christine Edwards ◽  
Julie C. Locklear ◽  
Marcia F. T. Rupnow ◽  
Ronald J. Diamond
Keyword(s):  
Cost Effectiveness ◽  
Antipsychotic Agents ◽  
The Usa ◽  
Long Acting

scholarly journals Cost–effectiveness of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA

2018 ◽  
Vol 7 (7) ◽  
pp. 637-650 ◽  
Author(s):  
Margarida Augusto ◽  
Mallik Greene ◽  
Maëlys Touya ◽  
Samantha Min Sweeney ◽  
Heidi Waters
Keyword(s):  
Cost Effectiveness ◽  
Bipolar I Disorder ◽  
The Usa ◽  
Long Acting

scholarly journals Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β2-agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study

BMJ Open ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. e049675
Author(s):  
Martine Hoogendoorn ◽  
Isaac Corro Ramos ◽  
Stéphane Soulard ◽  
Jennifer Cook ◽  
Erkki Soini ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
The Netherlands ◽  
Cost Effective ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Inhaled Corticosteroid ◽  
Dose Combination ◽  
Long Acting ◽  
Β2 Agonist ◽  
Country Specific

ObjectivesChronic obstructive pulmonary disease (COPD) guidelines advocate treatment with combinations of long-acting bronchodilators for patients with COPD who have persistent symptoms or continue to have exacerbations while using a single bronchodilator. This study assessed the cost-utility of the fixed dose combination of the bronchodilators tiotropium and olodaterol versus two comparators, tiotropium monotherapy and long-acting β2 agonist/inhaled corticosteroid (LABA/ICS) combinations, in three European countries: Finland, Sweden and the Netherlands.MethodsA previously published COPD patient-level discrete event simulation model was updated with most recent evidence to estimate lifetime quality-adjusted life years (QALYs) and costs for COPD patients receiving either tiotropium/olodaterol, tiotropium monotherapy or LABA/ICS. Treatment efficacy covered impact on trough forced expiratory volume in 1 s (FEV1), total and severe exacerbations and pneumonias. The unit costs of medication, maintenance treatment, exacerbations and pneumonias were obtained for each country. The country-specific analyses adhered to the Finnish, Swedish and Dutch pharmacoeconomic guidelines, respectively.ResultsTreatment with tiotropium/olodaterol gained QALYs ranging from 0.09 (Finland and Sweden) to 0.11 (the Netherlands) versus tiotropium and 0.23 (Finland and Sweden) to 0.28 (the Netherlands) versus LABA/ICS. The Finnish payer’s incremental cost-effectiveness ratio (ICER) of tiotropium/olodaterol was €11 000/QALY versus tiotropium and dominant versus LABA/ICS. The Swedish ICERs were €6200/QALY and dominant, respectively (societal perspective). The Dutch ICERs were €14 400 and €9200, respectively (societal perspective). The probability that tiotropium/olodaterol was cost-effective compared with tiotropium at the country-specific (unofficial) threshold values for the maximum willingness to pay for a QALY was 84% for Finland, 98% for Sweden and 99% for the Netherlands. Compared with LABA/ICS, this probability was 100% for all three countries.ConclusionsBased on the simulations, tiotropium/olodaterol is a cost-effective treatment option versus tiotropium or LABA/ICS in all three countries. In both Finland and Sweden, tiotropium/olodaterol is more effective and cost saving (ie, dominant) in comparison with LABA/ICS.

Sustained drug delivery optimizes long-term treatment of patients with schizophrenia

2004 ◽  
Vol 16 (6) ◽  
pp. 319-325 ◽  
Author(s):  
Pierre S. Chue ◽  
Peter D'Hoore ◽  
J. Michael Ramstack
Keyword(s):  
Antipsychotic Agents ◽  
Term Treatment ◽  
Treatment Programs ◽  
Sustained Drug Delivery ◽  
Partial Compliance ◽  
Long Term Treatment ◽  
Optimal Maintenance ◽  
Long Acting ◽  
The Impact

Chronic disorders such as schizophrenia require long-term treatment programs in order to maintain patients at the lowest level of symptomatology, reduce the likelihood of psychotic relapse, and support achievement of remission and recovery. Evidence suggests that treatment with long-acting injectable antipsychotics reduces the impact of partial compliance and provides predictable release of medication, assuring continuous therapeutic coverage. Until recently, only conventional antipsychotic agents were available in long-acting formulations, thereby foregoing the advantages of the atypical class. Atypical agents which are given orally have been shown to provide long-term efficacy and tolerability benefits compared with conventional agents, but are limited by the need for daily administration. The most recent pharmacological strategy to achieve optimal maintenance treatment has been to combine the benefits of an atypical antipsychotic with delivery in a water-based long-acting formulation. The first antipsychotic to achieve this combination – long-acting risperidone – may thus represent an important advance in the optimization of long-term treatment outcomes in patients with schizophrenia.

Reliability Data Collection for Ship Machinery

1998 ◽  
Vol 35 (02) ◽  
pp. 119-125
Author(s):  
Bahadir lnozu ◽  
Peter G. Schaedel ◽  
Veronique Molinari ◽  
Philippe Roy ◽  
Robert Johns
Keyword(s):  
Cost Effectiveness ◽  
Data Collection ◽  
Gulf Coast ◽  
Global Scale ◽  
Cooperative Program ◽  
Seed Funding ◽  
The Usa ◽  
The University ◽  
Life Cycle Development ◽  
Gulf Coast Region

An industry-wide international network is needed to collect Reliability, Availability and Maintainability (RAM) data on shipboard machinery and share this data at different levels by linking vessel chief engineers, ship operators-managers, regulatory agencies, equipment manufacturers, and shipyards/designers. This network should facilitate the efficient collection and flow of RAM information between these entities with industry-wide continuous improvement in safety and cost-effectiveness. This paper describes the implementation of a worldwide information network, called RAM/SHIPNET to support the optimization of safety, reliability and cost effectiveness throughout all stages of a vessel's life cycle. Development of this network was started with seed funding from SNAME and continued under the umbrella of the Ship Operations Cooperative Program with primary funding from the Gulf Coast Region Maritime Technology Center at the University of New Orleans. First generation data collection and processing tools have been completed and, pilot validation and testing has been performed in the USA. The project is now moving into the second implementation stage enabling full scale testing, validation and roll-out on a global scale. A call is made to the industry for suggestions on improvement to meet emerging needs.

Sign in / Sign up

Export Citation Format

Share Document